Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma
Open Access
- 13 November 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 51 (4), 1237-1243
- https://doi.org/10.1002/hep.23437
Abstract
Liver transplantation is an important treatment option for selected patients with nonresectable hepatocellular carcinoma (HCC). Several reports have suggested a lower risk of posttransplant tumor recurrence with the use of sirolimus and a higher one with calcineurin inhibitors, but the selection of an ideal immunosuppression protocol is still a matter of debate. The aim of this study was to define the immunosuppression associated with the best survival after liver transplantation for HCC. It was based on the Scientific Registry of Transplant Recipients and included 2,491 adult recipients of isolated liver transplantation for HCC and 12,167 for non-HCC diagnoses between March 2002 and March 2009. All patients remained on stable maintenance immunosuppression protocols for at least 6 months posttransplant. In a multivariate analysis, only anti-CD25 antibody induction and sirolimus-based maintenance therapy were associated with improved survivals after transplantation for HCC (hazard ratio [HR] 0.64, 95% confidence interval [CI]: 0.45–0.9, P ≤ 0.01; HR 0.53, 95% CI: 0.31–0.92, P ≤ 0.05, respectively). The other studied drugs, including calcineurin inhibitors, did not demonstrate a significant impact. In an effort to understand whether the observed effects were due to a direct impact of the drug on tumor or more on liver transplant in general, we conducted a similar analysis on non-HCC patients. Although anti-CD25 induction was again associated with a trend toward improved survival, sirolimus showed a trend toward lower rates of survival in non-HCC recipients, confirming the specificity of its beneficial impact to cancer patients. Conclusion: According to these data, sirolimus-based immunosuppression has unique posttransplant effects on HCC patients that lead to improved survival. (HEPATOLOGY 2010.)Keywords
This publication has 21 references indexed in Scilit:
- Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT’ StudyAmerican Journal of Transplantation, 2009
- Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients databaseHepatology, 2008
- Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin InhibitorsAnnals of Surgery, 2008
- Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular CarcinomaClinical Cancer Research, 2008
- Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinomaLiver Transplantation, 2008
- Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinomaLiver Transplantation, 2008
- De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side EffectsTransplantation, 2007
- Incisional hernia following liver transplantation: incidence and predisposing factorsClinical Transplantation, 2007
- Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGFBlood, 2005
- Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinomaLiver Transplantation, 2004